Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab

Ann Oncol. 1999 Nov;10(11):1393-4. doi: 10.1023/a:1008365216323.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Cisplatin / administration & dosage
  • Drug Resistance, Neoplasm
  • Follow-Up Studies
  • Genes, erbB-2 / genetics*
  • Germinoma / drug therapy*
  • Germinoma / genetics*
  • Germinoma / pathology
  • Humans
  • Male
  • Middle Aged
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / genetics
  • Trastuzumab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Trastuzumab
  • Cisplatin